Drug
Ensifentrine Twice Daily
Ensifentrine Twice Daily: highest development phase Phase 3, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ensifentrine 3 mg twice daily NCT06460493 | Phase 3 | COPD |
Latest
No recent events.
Follow Ensifentrine Twice Daily on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.